177 related articles for article (PubMed ID: 20082362)
21. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
Polley MY; Cheung YK
Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
[TBL] [Abstract][Full Text] [Related]
22. Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpoint.
Padmanabhan SK; Dragalin V
Biom J; 2010 Dec; 52(6):836-52. PubMed ID: 20891026
[TBL] [Abstract][Full Text] [Related]
23. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs.
Gardner SN
Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous beam geometry and intensity map optimization in intensity-modulated radiation therapy.
Lee EK; Fox T; Crocker I
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):301-20. PubMed ID: 16289912
[TBL] [Abstract][Full Text] [Related]
25. Two-stage design for dose-finding that accounts for both efficacy and safety.
Dragalin V; Fedorov VV; Wu Y
Stat Med; 2008 Nov; 27(25):5156-76. PubMed ID: 18680164
[TBL] [Abstract][Full Text] [Related]
26. Estimation for the optimal combination of markers without modeling the censoring distribution.
Chiang CT; Huang SY
Biometrics; 2009 Mar; 65(1):152-8. PubMed ID: 18422791
[TBL] [Abstract][Full Text] [Related]
27. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
De Ridder F
Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
[TBL] [Abstract][Full Text] [Related]
28. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
29. Linear mixed-effect multivariate adaptive regression splines applied to nonlinear pharmacokinetics data.
Gries JM; Verotta D
J Biopharm Stat; 2000 Aug; 10(3):383-98. PubMed ID: 10959918
[TBL] [Abstract][Full Text] [Related]
30. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
Jordan P; Brunschwig H; Luedin E
Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
[TBL] [Abstract][Full Text] [Related]
31. Applying the law of iterated logarithm to control type I error in cumulative meta-analysis of binary outcomes.
Hu M; Cappelleri JC; Lan KK
Clin Trials; 2007; 4(4):329-40. PubMed ID: 17848494
[TBL] [Abstract][Full Text] [Related]
32. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
33. Bayesian nonparametric estimation of continuous monotone functions with applications to dose-response analysis.
Bornkamp B; Ickstadt K
Biometrics; 2009 Mar; 65(1):198-205. PubMed ID: 18510655
[TBL] [Abstract][Full Text] [Related]
34. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
Resche-Rigon M; Zohar S; Chevret S
Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
[TBL] [Abstract][Full Text] [Related]
35. A shared response model for clustered binary data in developmental toxicity studies.
Pang Z; Kuk AY
Biometrics; 2005 Dec; 61(4):1076-84. PubMed ID: 16401281
[TBL] [Abstract][Full Text] [Related]
36. Supplementary analysis of probabilities at the termination of a group sequential phase II trial.
Liu A; Wu C; Yu KF; Gehan E
Stat Med; 2005 Apr; 24(7):1009-27. PubMed ID: 15565737
[TBL] [Abstract][Full Text] [Related]
37. A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.
Hall DB; Meier U; Diener HC
Contemp Clin Trials; 2005 Jun; 26(3):349-64. PubMed ID: 15911469
[TBL] [Abstract][Full Text] [Related]
38. A simulation study to assess statistical methods for binary repeated measures data.
Masaoud E; Stryhn H
Prev Vet Med; 2010 Feb; 93(2-3):81-97. PubMed ID: 20004989
[TBL] [Abstract][Full Text] [Related]
39. Optimal designs for estimating the most successful dose.
Zohar S; O'Quigley J
Stat Med; 2006 Dec; 25(24):4311-20. PubMed ID: 16969893
[TBL] [Abstract][Full Text] [Related]
40. Marginalized models for moderate to long series of longitudinal binary response data.
Schildcrout JS; Heagerty PJ
Biometrics; 2007 Jun; 63(2):322-31. PubMed ID: 17688485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
